cell
express
angiotensinconvert
enzym
protein
engag
receptorbind
domain
rbd
independ
fold
acid
fragment
acid
sprotein
protom
antibodi
rbd
domain
sarscov
close
relat
coronaviru
emerg
shown
potent
neutral
sproteinmedi
entri
presenc
antirbd
antibodi
correl
neutral
convalesc
sera
show
immun
rbd
elicit
robust
neutral
antibodi
respons
rodent
compar
potent
entri
inhibitor
importantli
antisera
immun
anim
mediat
antibodi
depend
enhanc
ade
sproteinmedi
entri
condit
zika
could
safe
effect
biorxiv
preprint
acut
respiratori
syndrom
coronaviru
spike
protein
membran
fusion
reduc
viral
control
humor
immun
respons
crossneutr
human
palm
civet
sever
acut
respiratori
syndrom
coronavirus
antibodi
target
receptorbind
domain
spike
protein
coronavirus
envelop
singlestrand
positivestrand
rna
virus
famili
corornavirida
cui
et
al
divid
four
main
subgroup
least
seven
coronavirus
infect
human
sarscov
merscov
recent
describ
close
relat
human
nucleotid
ident
sarscovlik
variant
isol
bat
includ
nucleotid
ident
lu
et
al
menacheri
et
al
zhou
et
al
infect
caus
mild
flulik
symptom
mani
patient
mani
case
develop
acut
pulmonari
syndrom
chen
et
al
zhou
et
al
caus
sever
acut
respiratori
syndrom
sar
wherea
diseas
associ
name
like
requir
express
cellular
receptor
infect
cell
hoffmann
et
al
li
et
al
wall
et
al
carboxi
metalloproteas
among
substrat
cleav
angiotensin
angiotensin
angiotensin
ii
angiotensin
respect
angiotensin
angiotensin
counteract
vasoconstrict
activ
ham
et
al
jia
although
catalyt
domain
similar
inhibitor
effect
enzymat
activ
moreov
proteolyt
activ
contribut
presum
entri
process
li
et
al
howev
interfer
activ
sproteinpromot
intern
degrad
trigger
releas
cellular
proteas
loss
type
ii
pneumocyt
may
contribut
sar
patholog
although
physiolog
role
complex
activ
describ
protect
acut
respiratori
distress
syndrom
ard
caus
mani
agent
imai
et
al
howev
administr
solubl
recombin
although
well
toler
attenu
acut
lung
injuri
earli
clinic
studi
ard
unrel
khan
et
al
entri
cell
mediat
spike
protein
hoffmann
et
al
wall
et
al
coronaviru
protein
type
viral
entri
protein
similar
influenza
hemagglutinin
envelop
glycoprotein
figur
li
like
latter
entri
protein
protein
process
two
domain
wall
et
al
bind
wherea
anchor
protein
viral
membran
protein
effici
furin
cleavag
site
boundari
site
process
virusproduc
cell
coutard
et
al
contrast
junction
cleav
extracellular
targetcel
proteas
includ
cathepsin
l
glowacka
et
al
huang
et
al
millet
whittak
protein
requir
process
second
site
within
domain
mediat
fusion
viral
target
cell
membran
belouzard
et
al
receptorbind
domain
rbd
also
describ
b
directli
bind
figur
li
et
al
wall
et
al
wong
et
al
wrapp
et
al
rbd
structur
function
distinct
remaind
domain
express
fold
independ
domain
wong
et
al
rbd
highli
stabl
held
togeth
four
disulfid
bond
structur
studi
rbd
bound
identifi
variabl
region
term
receptorbind
motif
rbm
directli
engag
li
et
al
region
diverg
figur
although
rbd
bind
orient
reli
conserv
mostli
aromat
residu
engag
receptor
diverg
rbm
domain
suggest
region
subject
ongo
posit
select
humor
respons
variou
host
despit
diverg
antibodi
notabl
bind
rbd
domain
tian
et
al
protein
domin
protein
expos
virion
activ
imped
antibodi
like
major
target
vaccin
solubl
trimer
protein
includ
stabil
variou
mechan
test
vaccin
similar
approach
taken
chen
et
al
wall
et
al
wrapp
et
al
anoth
approach
immun
rbd
alon
shown
rais
potent
neutral
antibodi
rodent
et
al
et
al
although
rbd
present
fewer
epitop
sprotein
trimer
approach
may
key
advantag
rbd
easier
produc
less
like
elicit
antibodi
poorli
neutral
immunogen
epitop
addit
antibodydepend
enhanc
ade
contribut
pathogen
felin
coronavirus
huisman
et
al
olsen
et
al
weiss
scott
rais
concern
vaccin
jaum
et
al
liu
et
al
luo
et
al
wan
et
al
wang
et
al
wang
et
al
yang
et
al
yip
et
al
ade
contribut
patholog
viral
diseas
notabl
caus
flavivirus
case
nonneutr
antibodi
promot
effici
ade
also
neutral
dejnirattisai
et
al
halstead
orourk
takada
kawaoka
thu
rbdelicit
antibodi
may
mediat
ade
less
effici
recogn
sprotein
epitop
like
neutral
accordingli
investig
whether
rbd
domain
could
rais
effici
neutral
antibodi
whether
antibodi
could
also
mediat
ade
show
rbd
rais
potent
neutral
antisera
immun
rat
sera
mediat
ade
condit
zikaviru
ade
readili
observ
rbd
like
expos
known
state
sprotein
trimer
name
close
state
rbd
contact
symmetr
analogu
protom
figur
open
state
figur
least
one
rbd
domain
extend
contact
figur
previous
shown
rbd
fold
independ
express
effici
immunoadhesin
form
rbd
neutral
sprotein
mediat
entri
inhibitor
concentr
nm
wong
et
al
construct
rbdfc
also
effici
rais
antibodi
mice
capabl
neutral
variant
distinct
rbd
sequenc
et
al
et
al
previou
data
rais
possibl
rbdbase
vaccin
could
effect
viru
throughout
current
pandem
evalu
possibl
produc
purifi
rbd
sequenc
shown
figur
fuse
fc
domain
expedi
rapid
purif
rbd
fusion
protein
conjug
keyhol
limpet
hemocyanin
klh
carrier
protein
mix
adjuv
formul
use
least
two
human
vaccin
antigenadjuv
combin
inject
intramuscularli
four
femal
spraguedawley
rat
schedul
seven
increas
dose
one
day
ultim
administ
total
sarscov
rbdfc
thirti
day
first
administr
rbd
fuse
acid
ctag
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
purifi
ctag
affin
column
conjug
klh
immun
regimen
repeat
total
rbd
administ
blood
harvest
four
rat
immedi
inocul
day
interv
start
day
first
inocul
serial
dilut
sera
measur
abil
neutral
retrovirus
pseudotyp
protein
provid
consist
metric
neutral
potenc
sera
also
compar
mixtur
four
preimmun
sera
combin
immunoadhesin
form
concentr
sera
dilut
anticip
baselin
inhibit
could
observ
heatinactiv
rat
sera
grey
line
figur
howev
serum
rat
obtain
two
set
immun
potent
neutral
entri
effici
compar
greater
presera
mix
concentr
figur
inde
serum
one
four
rat
neutral
effici
mgml
mix
preimmun
serum
context
concentr
igg
rat
serum
approxim
mgml
medesan
et
al
context
rat
presera
appear
well
nm
dilut
preimmun
sera
neutral
entri
figur
inhibit
greater
observ
moor
et
al
consist
higher
affin
rbd
wall
et
al
wrapp
et
al
conclud
rbd
elicit
neutral
respons
vaccin
rat
compar
concentr
inhibitor
nm
character
effect
two
success
set
immun
compar
sera
pool
sera
rat
also
compar
pool
serum
mix
dilut
indic
figur
serum
potent
neutral
sproteinmedi
entri
significantli
greater
effici
serum
mix
lower
dilut
serum
neutral
effici
serum
somewher
preserum
howev
serum
effici
neutral
retrovirus
pseudotyp
protein
except
lowest
dilut
exclud
possibl
immun
singl
rbd
could
protect
sarslik
virus
diverg
rbd
final
confirm
sera
vaccin
rat
neutral
recogn
protein
use
pool
serum
displac
variant
rabbit
fc
domain
cell
express
protein
figur
abil
pool
serum
displac
correl
abil
neutral
specif
sera
displac
effici
preimmun
sera
contain
sera
displac
effici
preimmun
sera
contain
thu
immun
rbd
elicit
antibodi
potent
neutral
sprotein
mediat
entri
directli
bind
protein
one
concern
associ
coronaviru
vaccin
possibl
antisprotein
antibodi
could
increas
effici
infect
cell
alveolar
macrophag
express
fc
receptor
exampl
undesir
antibodydepend
enhanc
ade
well
character
tissuecultur
studi
sever
flavivirus
includ
zika
viru
zikv
dengu
viru
shim
et
al
evalu
possibl
mix
pool
serum
indic
serial
dilut
result
virussera
mixtur
incub
cell
transfect
express
rat
cell
express
infect
observ
preimmun
sera
immun
sera
figur
verifi
cell
capabl
mediat
ade
rat
antizikv
antisera
gener
two
differ
rat
pool
preimmun
sera
incub
dilut
zikv
viruslik
particl
vlp
contrast
absenc
effect
antirbd
antisera
antizikv
antisera
concentr
promot
robust
ade
figur
ade
activ
peak
approxim
dilut
consist
competit
ade
neutral
activ
antisera
determin
ade
could
observ
presenc
receptor
cell
stabli
express
transfect
express
rat
preimmun
sera
detect
impact
infect
wherea
serum
effici
neutral
infect
figur
howev
serum
promot
infect
serum
dilut
antizikv
antiserum
promot
robust
ade
zikv
vlp
figur
thu
antirbd
antiserum
promot
ade
serum
dilut
condit
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
zikv
ade
could
easili
observ
final
confirm
result
shown
figur
b
use
cell
endogen
express
chiofalo
et
al
sera
enhanc
entri
sarspv
entri
rat
antizikv
antisera
robustli
promot
zikvvlp
infect
figur
collect
data
figur
suggest
antibodi
elicit
rbdbase
vaccin
like
neutral
effici
would
mediat
ade
vaccin
sever
reason
easier
gener
mani
virus
gralinski
baric
li
first
coronavirus
except
larg
genom
compar
rna
virus
avoid
error
catastroph
viral
polymeras
acquir
proofread
function
thu
individu
gene
exampl
protein
like
retain
origin
sequenc
multipl
replic
cycl
second
coronavirus
gener
clearli
particular
transmit
new
host
rapidli
adapt
immun
respons
emerg
like
consequ
strategi
one
critic
epitop
name
rbd
expos
virion
li
wall
et
al
wong
et
al
wrapp
et
al
favor
transmiss
effici
antibodi
resist
final
stabil
compact
rbd
mean
easili
manufactur
present
immun
system
use
mani
product
technolog
present
scaffold
deliveri
system
wong
et
al
mani
effort
underway
develop
vaccin
base
stabil
solubl
trimer
form
protein
ectodomain
wrapp
et
al
moment
unclear
whether
sprotein
trimer
rbd
parallel
serial
combin
thereof
make
better
antigen
recent
studi
suggest
neutral
activ
patient
sera
correl
rbd
recognit
neutral
antibodi
bind
rbd
et
al
possibl
remaind
protein
present
nonneutr
epitop
immunogen
rbd
thu
rbd
may
elicit
antisera
neutral
howev
antibodi
effector
function
includ
antibodydepend
cellmedi
cytotox
adcc
complement
fixat
effici
activ
multipl
antibodi
bind
target
simultan
nonneutr
activ
play
import
role
viral
control
activ
contribut
significantli
prevent
sprotein
trimer
may
make
better
antigen
rbd
altern
optim
combin
antigen
may
focu
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
immun
respons
critic
neutral
epitop
also
promot
effici
antibodi
effector
function
trimerprim
rbdboost
strategi
may
even
necessari
luo
et
al
wang
et
al
yip
et
al
ade
observ
sever
group
cell
cultur
studi
jaum
et
al
liu
et
al
wan
et
al
wang
et
al
yang
et
al
yip
et
al
ade
obviou
felin
coronaviru
result
shift
tropism
increas
diseas
sever
huisman
et
al
huisman
et
al
weiss
scott
although
ade
could
theoret
mediat
multipl
mechan
standard
paradigm
provid
flavivirus
notabl
dengu
viru
takada
kawaoka
well
appreci
second
dengu
viru
infect
differ
serotyp
result
hemorrhag
fever
addit
dengueviru
vaccin
report
increas
hospit
vaccine
first
dengueviru
exposur
flips
smit
tsai
et
al
case
underli
mechan
presum
enhanc
fcreceptormedi
intern
virion
bound
antibodi
observ
flavivirus
qualit
differ
ade
mediat
neutral
nonneutr
antibodi
dejnirattisai
et
al
shim
et
al
takada
et
al
case
neutral
antibodi
ade
consequ
insuffici
coat
virion
surfac
due
lower
affin
concentr
antibodi
concentr
affin
rais
neutral
domin
contrast
ade
mediat
nonneutr
antibodi
increas
increas
concentr
therefor
specul
would
difficult
observ
ade
rat
antisera
target
rbd
key
neutral
epitop
inde
although
rat
antizika
viru
antisera
mediat
robust
ade
zikv
two
differ
fc
receptorexpress
cell
line
ade
sprotein
pseudovirus
observ
antirbd
antisera
whether
receptor
present
data
suggest
least
rbdbase
vaccin
ade
like
less
concern
vaccin
flavivirus
zikv
dengu
virus
howev
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
exclud
ade
mediat
sprotein
epitop
mechan
vaccin
deleteri
key
remain
question
whether
studi
conduct
rodent
impli
rbdbase
vaccin
could
effect
human
experiment
detail
becom
import
immun
rat
adjuv
system
alreadi
human
use
notabl
vaccin
shingl
shingrix
tm
malaria
mosquirix
tm
rbd
use
conjug
carrier
protein
keyhol
limpet
hemocyanin
proven
safe
decad
human
swaminathan
et
al
howev
klh
problemat
shellfish
allergi
altern
scaffold
present
rbd
may
necessari
rat
immun
two
set
escal
inocul
administ
seven
day
strategi
shown
maxim
immun
respons
antigen
tam
et
al
may
practic
mean
address
current
pandem
subunit
vaccin
said
escal
dosag
strategi
use
may
accur
reflect
kinet
mrnadeliv
vaccin
inde
would
argu
rbd
antigen
would
prefer
altern
least
use
complement
mrna
express
sprotein
trimer
howev
remain
determin
whether
limit
number
inject
rbd
subunit
vaccin
would
rais
protect
respons
key
point
relev
question
neutral
activ
elicit
studi
like
much
greater
would
necessari
prevent
new
infect
rat
antisera
averag
neutral
effici
naiv
sera
bear
neutral
less
consist
activ
infecti
moor
et
al
provid
context
number
immunoadhesin
emul
viral
receptor
neutral
neutral
potenc
similar
afford
robust
protect
highdos
intraven
challeng
viru
present
serum
rang
gardner
et
al
gardner
et
al
thu
possibl
less
robust
respons
could
still
protect
perhap
import
quantit
consider
data
show
rbd
alon
suffici
elicit
potent
neutral
antibodi
respons
remain
determin
whether
trimerbas
vaccin
trimerrbd
combin
effect
whether
carri
addit
safeti
concern
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
short
data
suggest
rbd
vaccin
could
protect
mani
individu
unlik
promot
infect
convent
ade
mechan
given
exposur
key
neutral
epitop
eas
compact
domain
produc
present
clear
immunogen
propos
rbd
consid
key
compon
vaccin
strategi
tian
x
li
c
huang
xia
lu
shi
z
lu
l
jiang
yang
z
wu
et
al
provid
critic
reagent
advic
mf
wrote
manuscript
critic
assist
hc
inform
request
resourc
reagent
direct
fulfil
michael
farzan
farzan
scrippsedu
retrovirus
pseudotyp
protein
produc
previous
describ
moor
et
al
modest
modif
describ
cell
transfect
polyethylenimin
pei
transfect
ratio
plasmid
encod
murin
leukemia
viru
mlv
gagpol
protein
retrovir
vector
pqcxix
express
firefli
luciferas
plasmid
express
spike
protein
genbank
genbank
cell
wash
hour
later
cultur
supernat
contain
pseudovirus
harvest
hour
post
transfect
zika
viru
viruslik
particl
zikvvlp
produc
transfect
cell
calcium
phosphat
transfect
method
zikv
replicon
strain
genbank
whose
express
control
tetracyclin
plasmid
encod
zikv
capsid
prm
e
protein
strain
genbank
pteton
plasmid
express
revers
tetrespons
transcript
activ
rtta
ratio
cell
wash
h
later
replenish
fresh
media
contain
doxycyclin
vlpcontain
cultur
supernat
harvest
h
post
transfect
zikv
replicon
gener
replac
region
span
th
rd
amino
acid
polyprotein
zikv
molecular
clone
previous
gener
zhang
et
al
renilla
luciferas
selfcleav
peptid
fuse
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
cterminu
construct
contain
tetracyclinrespons
ptight
promot
drive
zikv
rna
transcript
pseudovirusor
vlpcontain
cultur
supernat
clear
filtrat
zikvvlp
titer
assess
rtqpcr
target
cmv
promot
retrovir
vector
pqcxix
zikv
gene
respect
case
clarifi
pseudoviru
vlp
stock
store
c
longterm
storag
reus
cell
express
human
gener
transduct
murin
leukemia
viru
mlv
pseudotyp
vesicular
stomat
viru
g
protein
express
previous
describ
wicht
et
al
briefli
cell
cotransfect
pei
three
plasmid
pmlvgagpol
pcaggsvsvg
ratio
medium
refresh
overnight
incub
transfect
mix
supernat
produc
viru
harvest
post
transfect
clarifi
pass
filter
cell
select
maintain
medium
contain
puromycin
sigma
express
confirm
entri
assay
immunofluoresc
stain
use
mous
monoclon
antibodi
recogn
cmyc
cell
thermofish
transient
transfect
use
fectopro
polyplu
plasmid
encod
rbd
human
rabbitfc
fusion
ctermin
ctag
epea
day
shaker
cultur
media
collect
clear
debri
min
g
nd
filter
use
flask
nalgen
protein
isol
use
mabselect
sure
ge
lifesci
captureselect
ctagxl
thermofish
column
accord
manufactur
instruct
eluat
buffer
exchang
pb
concentr
use
amicon
ultra
filtrat
devic
millipor
sigma
store
use
rat
use
studi
handl
maintain
accord
nih
guidelin
approv
institut
anim
care
use
committe
iacuc
scripp
research
protocol
femal
spragu
dawley
rat
immun
increment
increas
dose
antigen
seven
day
start
day
boost
similar
regimen
day
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
serial
dilut
sera
dope
wash
cell
stain
antirabbit
antibodi
minut
mean
fluoresc
intens
measur
well
flow
cytometri
abil
rbd
immun
plasma
mediat
antibodydepend
enhanc
ade
measur
use
cell
cell
stabli
express
human
cell
transfect
use
calcium
phosphat
transfect
method
express
rat
ortholog
human
monocyt
cell
line
atcc
endogen
express
also
use
ade
assay
rbd
immun
sera
collect
four
differ
rat
day
first
immun
mix
equal
ratio
preimmun
sera
obtain
day
rat
posit
control
sera
zikvinfect
rat
rat
distinct
similarli
number
rbdinocul
rat
also
mix
equal
ratio
immun
preimmun
serum
sampl
heat
inactiv
min
serial
dilut
dmem
contain
heatinactiv
fb
zikvvlp
preincub
h
dilut
sera
ad
indic
cell
plate
well
plate
two
day
later
infect
level
assess
use
lucpair
firefli
luciferas
hs
assay
kit
genocopia
sarspv
lucpair
renilla
luciferas
hs
assay
kit
genocopia
zikvvlp
statist
signific
differ
preimmun
immun
sera
abil
neutral
bind
protein
mediat
ade
analyz
twoway
anova
calcul
use
graphpad
prism
differ
consid
signific
p
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
four
femal
spragu
dawley
rat
immun
two
set
escal
dose
rbd
conjug
keyhol
limpet
hemocyanin
indic
dilut
preimmun
sera
day
gray
compar
dilut
sera
harvest
immun
rat
day
dilut
preimmun
sera
mix
achiev
indic
concentr
dilut
serum
mixtur
compar
abil
neutral
sproteinpseudotyp
retrovirus
measur
activ
fireflylucifereas
report
express
pseudovirus
figur
show
entri
percentag
observ
without
ad
rat
serum
error
bar
indic
rang
two
neutral
studi
b
data
rat
panel
averag
clariti
error
bar
indic
sem
rat
consid
differ
experi
differ
serum
signific
dilut
p
twoway
anova
c
sera
rat
pool
character
entri
measur
indic
dilut
preimmun
sera
sera
sera
compar
sera
mix
achiev
indic
concentr
dilut
character
abil
neutral
day
sera
also
test
abil
neutral
pseudovirus
indic
valu
shown
indic
percentag
pseudoviru
entri
observ
dilut
preimmun
sear
signific
differ
compar
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
serum
dilut
indic
bar
indic
p
indic
p
indic
p
indic
p
ns
indic
p
twoway
anova
error
bar
indic
rang
two
entri
assay
pool
sera
pool
preimmun
sera
mix
indic
concentr
combin
variant
bear
rabbitderiv
fc
domain
bind
monitor
antirabbit
fc
secondari
antibodi
determin
flow
cytometri
error
bar
indic
rang
two
measur
differ
serum
signific
p
twoway
anova
dilut
